Lisa Rosenbaum.

Second, letting the market form usability assumes that clinicians will be the focus on users. So EHRs will be just as good as the product quality metrics they’re designed to capture; technology can’t conquer fundamental measurement issues. We measure a lot of things that have no value to patients, while a lot of what individuals do value, including our attention, remains unmeasurable. Why, Wachter asks, do we do nothing similar in health care? In a moving passage, Wachter speaks with a famous surgeon who once spent his evenings before surgery reading his notes on another day’s patients. No longer. His notes have been rendered homogeneous by the tyranny of clicks and auto-populated fields uselessly.Received acceptance and APP Pharmaceuticals launched Gemcitabine HCI for Injection in the 200 mg and 1g dosage forms within a commercialization, manufacture and offer agreement with Teva. According to IMS Health data, 2010 branded product sales of all dosage strengths of Gemcitabine HCI for Injection in the United States were around $780 million. Sales of the generic 2 g dosage power accounted for $33.3 million, with 36,from November 2010 thru March 2011 000 units sold. ‘With the acceptance of the two 2 g dosage, APP becomes the only generic manufacturer to provide its customers all three dosage strengths of this critically important oncology medication,’ said John Ducker, President and Chief Executive Officer of APP Pharmaceuticals.